Supplementary Figure 2: The Mdr-1 inhibitor TQD preferably increases brain concentrations of FK506 and rifampicin in the ischemic brain. Blood concentrations (a, c) and brain-to-blood-concentration ratios in the contralateral non-ischemic and lesion-sided ischemic tissue (b, d) are shown for mice submitted to 30 min of MCA occlusion that were intravenously treated with FK506 (3 mg kg⁻¹) or TQD (8 mg kg⁻¹) / FK506 (3 mg kg⁻¹) (a, b), or with rifampicin (20 mg kg⁻¹) or TQD (8 mg kg⁻¹) / rifampicin (20 mg kg⁻¹) (c, d). Animals were sacrificed 6 h after MCA occlusion. Brain samples were taken from the cortex and underlying striatum. Brain-to-blood concentration ratios are given as ng mg⁻¹ per µg ml⁻¹. Values are means ± S.D. (n = 4 / group [a, b]; n = 8 / group [c, d]). Data were analyzed by one-way ANOVA, followed by Scheffé-tests. In addition, two-way ANOVA were computed, for which condition x drug interaction effects are shown. *P < 0.05 / **P < 0.01 compared with FK506 / rifampicin only; ††P < 0.01 compared with contralateral.